Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

KSQ Therapeutics

https://ksqtx.com/

Latest From KSQ Therapeutics

Takeda Grows Immuno-Oncology Portfolio With $525m Maverick Acquisition

Maverick’s bispecific antibody program adds to Takeda’s expanding immuno-oncology development business, which also includes cell therapy programs.

Research & Development Deals

Takeda’s Andy Plump Tells The Japanese Pharma’s New Story

As Takeda pays down debt associated with the acquisition of Shire and advances R&D programs toward global filings, the company is selling its growth plan to investors – but are they buying?

Business Strategies Deals

Asia Deal Watch: Takeda, KSQ Take CRISPR Approach To T-Cell Oncology Therapy

Plus deals involving Astellas/Actinium, Sosei/PharmEnable, Aadi/EOC Pharma, BeiGene/Strand, Chi-Med/Inmagene, Alteogen/Intas, Sosei/AbbVie, Y-Biologics/3D Medicines.

Deals Business Strategies

Coronavirus Update: Coalition Aims To Overcome 'Disjointed' COVID-19 Trials, Gilead's Open Label Criticized

NIH's Collins brings together coalition after months of behind-the-scenes work. Meanwhile, Gilead's remdesivir trials are the center of huge expectation and controversy.

Clinical Trials Coronavirus COVID-19
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Drug Discovery Tools
      • Genomics-Proteomics
UsernamePublicRestriction

Register